|
Gene: PIK3AP1 |
Gene summary for PIK3AP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PIK3AP1 | Gene ID | 118788 |
Gene name | phosphoinositide-3-kinase adaptor protein 1 | |
Gene Alias | BCAP | |
Cytomap | 10q24.1 | |
Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q6ZUJ8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
118788 | PIK3AP1 | S43 | Human | Liver | Cirrhotic | 3.86e-02 | -1.26e-01 | -0.0187 |
118788 | PIK3AP1 | HCC1_Meng | Human | Liver | HCC | 1.36e-26 | -2.10e-01 | 0.0246 |
118788 | PIK3AP1 | HCC2_Meng | Human | Liver | HCC | 7.52e-09 | -2.44e-01 | 0.0107 |
118788 | PIK3AP1 | cirrhotic2 | Human | Liver | Cirrhotic | 1.50e-07 | 1.05e-01 | 0.0201 |
118788 | PIK3AP1 | cirrhotic3 | Human | Liver | Cirrhotic | 3.68e-04 | -1.05e-01 | 0.0215 |
118788 | PIK3AP1 | HCC2 | Human | Liver | HCC | 3.96e-10 | 3.93e+00 | 0.5341 |
118788 | PIK3AP1 | Pt13.b | Human | Liver | HCC | 1.74e-05 | -1.46e-01 | 0.0251 |
118788 | PIK3AP1 | S014 | Human | Liver | HCC | 5.00e-06 | -3.10e-01 | 0.2254 |
118788 | PIK3AP1 | S015 | Human | Liver | HCC | 1.18e-03 | -3.10e-01 | 0.2375 |
118788 | PIK3AP1 | S016 | Human | Liver | HCC | 4.77e-08 | -3.10e-01 | 0.2243 |
118788 | PIK3AP1 | S028 | Human | Liver | HCC | 3.37e-04 | 5.44e-01 | 0.2503 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
GO:0002224 | Liver | HCC | toll-like receptor signaling pathway | 67/7958 | 121/18723 | 2.87e-03 | 1.34e-02 | 67 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3AP1 | SNV | Missense_Mutation | novel | c.2320N>C | p.Glu774Gln | p.E774Q | Q6ZUJ8 | protein_coding | tolerated(0.15) | probably_damaging(0.995) | TCGA-BA-5152-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PIK3AP1 | SNV | Missense_Mutation | novel | c.23G>A | p.Arg8Lys | p.R8K | Q6ZUJ8 | protein_coding | tolerated(0.58) | benign(0.009) | TCGA-BA-6871-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PIK3AP1 | SNV | Missense_Mutation | novel | c.116G>A | p.Ser39Asn | p.S39N | Q6ZUJ8 | protein_coding | tolerated(0.28) | benign(0) | TCGA-CQ-6225-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
PIK3AP1 | SNV | Missense_Mutation | novel | c.871N>G | p.Pro291Ala | p.P291A | Q6ZUJ8 | protein_coding | tolerated(0.07) | benign(0.146) | TCGA-H7-A76A-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PIK3AP1 | SNV | Missense_Mutation | novel | c.2309N>T | p.Thr770Ile | p.T770I | Q6ZUJ8 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PIK3AP1 | SNV | Missense_Mutation | c.2363N>A | p.Pro788His | p.P788H | Q6ZUJ8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PIK3AP1 | SNV | Missense_Mutation | rs201029174 | c.620N>T | p.Ala207Val | p.A207V | Q6ZUJ8 | protein_coding | tolerated(0.21) | benign(0.038) | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PIK3AP1 | SNV | Missense_Mutation | c.2413N>T | p.Arg805Cys | p.R805C | Q6ZUJ8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
PIK3AP1 | SNV | Missense_Mutation | c.2105N>C | p.Val702Ala | p.V702A | Q6ZUJ8 | protein_coding | tolerated(0.73) | benign(0.012) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
PIK3AP1 | SNV | Missense_Mutation | rs567912958 | c.512C>T | p.Thr171Met | p.T171M | Q6ZUJ8 | protein_coding | tolerated(0.12) | benign(0.08) | TCGA-SW-A7EA-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |